T he cataract Shionogi (CTS) strain of mouse was initially described in 1968 as having cataracts and micropthalmia and was later reported to have profound peripheral T cell deficiency (Ptcd) 1 . The nature of this defect, however, has remained unclear. In this issue of Nature Immunology, Cyster and colleagues map the genetic basis of the T cell deficiency in CTS mice and show that it is caused by a point mutation in Coro1a, the gene encoding the actin-regulating protein coronin 1A (Coro1A) 2 . By mapping a cross between CTS and C57BL/6 mice, they find that cataracts and microphthalmia fail to segregate with Ptcd. They further map the Ptcd locus to a 950-kilobase interval of DNA on chromosome 7, which contains 37 open reading frames, including Coro1a. By sequencing, they identify a G-to-A mutation in exon 2 of Coro1a that results in the substitution of lysine for a highly conserved glutamic acid residue at position 26. They confirm that this E26K substitution causes Ptcd by complementation with Coro1a +/-mice, in which the wild-type allele complements the phenotype but the null allele does not.
In collaboration with Chris Goodnow's group, they also report a new mutant mouse strain called 'Koyaanisqatsi' (Koy). This mouse, discovered in an N-ethyl-Nnitrosourea-induced mutagenesis screen, lacks peripheral T cells, and sequencing of Coro1a in the Koy strain shows an A-to-T mutation in exon 7 that leads to substitution of valine for aspartic acid at residue 278. Thymocytes from Koy mice have much less Coro1A protein, which suggests that this aspartic acid-to-valine substitution produces a Coro1A hypomorph mutant.
Turning their attention to human patients with severe combined immunodeficiency (SCID), they screen 16 people with primary T cell immunodeficiency for mutations in CORO1A. They find a single patient with a two-base pair deletion in exon 3 that results in a frameshift mutation and undetectable Coro1A expression, which suggests that this T cell-deficient, B cell-sufficient and NK cell-sufficient SCID was caused by loss of Coro1A. Notably, another mutation in mouse Coro1a has been identified as a disease-suppressing allele in the MRL model of lupus autoimmune disease 3 . In this case, suppression of disease by the Lmb3 allele is associated with peripheral T cell deficiency and impaired T cell-dependent B cell responses. The Lmb3 allele contains C-to-T transition at residue 784 that converts a glutamine to a stop codon (Q262X), which again leads to undetectable Coro1A protein. All these studies show that mutations in Coro1a cause profound peripheral T cell lymphopenia.
All the work by Cyster and colleagues arrives on the heels of work by two groups that have created Coro1A-deficient mice by gene targeting 4, 5 . The main defect of Coro1a-null T cells shown in those studies is impaired survival at the final stage of thymic maturation ( Fig. 1) , which leads to peripheral T cell deficiency. Coro1a -/-mice have normal numbers of 'semimature' single-positive (SP) cells, which suggests that positive selection is generally intact, but they have fewer 'mature' SP cells. Like Coro1a -/-mice, mice with the Lmb3-null allele or the Koy hypomorph mutation have a similar problem, with fewer mature SP thymocytes 2, 3 . Thymic progenitors from these mice die at the mature SP stage, as judged by upregulation of annexin V 2-4 . However, whether this is due to accumulation of F-actin 4 or an impaired calcium response 5 remains controversial.
One of the notable findings of the studies of Cyster and colleagues is that the E26K point substitution of Coro1A does not cause apoptosis at this stage; instead, mature SP are viable and accumulate in the thymus 2 ( Fig. 1) . The fact that the E26K mutant is not a precise 'phenocopy' of the null mutants allows the authors to make important conclusions about the function of Coro1A in T nature immunology volume 9 number 11 november 2008 1207
Immunodeficiency: when T cells are stuck at home cell survival and signaling. First, the E26K mutant has a modestly impaired T cell receptor-stimulated Ca 2+ flux similar to null cells, which suggests that a defective Ca 2+ flux does not cause the survival defect. The Ca 2+ flux of mutant thymocytes 2, 5 is not as impaired as that of peripheral T cells 3, 5 . This may be a biologically relevant observation or it may have to do with the compromised viability and function of the minor population of cells that make it to the periphery in these mice. As with many mutants that affect lymphocyte development, a good way to move forward is probably with inducible deficiency, in which lymphocytes are allowed to develop and emigrate normally, and then signaling, survival and apoptosis can be studied after induced deletion of the gene.
Second, Cyster and colleagues also report that thymocytes heterozygous for mutation causing the E26K substitution and the null allele survive but still have F-actin accumulation. This is unexpected because it suggests that F-actin accumulation alone does not cause cell death either. So the precise cause of the survival defect of Coro1a -/-mice remains incompletely understood. This will be an important issue to resolve because the transition from semimature SP to mature SP cell is critical during T cell development. This is the stage at which progenitors go from being to susceptible to apoptosis to having proliferation competence. Given that, it is surprising that little is known about the molecular factors involved in survival and differentiation at this final step. Mice lacking the apoptosisinhibitory molecule c-FLIP have a defect at this stage 6 , but it is unclear what the apoptosis-initiating signals are.
What is clear, however, is that all Coro1A mutants have motility defects [2] [3] [4] . The Coro1A E26K mutant mice are lymphopenic not because mature T cells fail to survive but because they fail to egress from the thymus. Mutant cells have good viability and normal expression of the sphingosine 1-phosphate receptor S1P 1 and chemokine receptors known to be involved in thymic emigration, but they do not migrate in response to sphingosine 1-phosphate or chemokines. Furthermore, they have impaired entry and exit from lymph nodes in adoptive transfer and have much less general motility, as assessed by two-photon microscopy. Biochemically, Coro1A E26K is more efficient than wild-type Coro1A in inhibiting the actin-nucleation activity of the actinnucleator protein Arp2/3, and it fails to localize to the leading edge of migrating cells 2 . Thus, the emigration defect seems to arise from an actin-remodeling defect 'downstream' of chemokine-lipid receptor signaling. This is consistent with the emigration defect of mice lacking another actin-nucleating protein, mDia1 (ref. 7) .
Notably, both mDia1-and Coro1A-deficient mutants seem to develop relatively normally up to the semimature SP stage (Fig. 1) , despite the fact that motility and chemokine responsiveness is impaired earlier, for example, in double-positive thymocytes. This is curious, because T cell development requires entry of progenitors from the blood into the thymus and involves several chemokine-dependent migratory events in the thymus 8 . Whether these earlier processes are impaired in subtle ways or are truly less dependent on actin remodeling activity remains to be determined. volume 9 number 11 november 2008 nature immunology Thus, antigens that subsequently encounter mature cDCs are inefficiently presented by these cDCs, as all their MHC class II molecules are already in use. Not known is whether plasmacytoid DCs (pDCs), which display relatively small amounts of MHC class II molecules on their surface, undergo similar alterations in MHC class II processing after maturation. Like cDCs, pDCs also change morphology and upregulate expression of MHC class II after activation. Thus, at first glance, it seems that presentation of MHC class II antigen should be similar in the two DC subsets. However, in this issue of Nature Immunology, Young and colleagues now show that the two DC types are fundamentally different in the way they handle MHC class II molecules and antigens 1 .
The pDCs seem to be less efficient in presenting exogenous ovalbumin on MHC class II molecules, perhaps as a result of inefficient fluid-phase uptake of antigens relative to that of cDCs. In addition, the rate of antigen degradation may be different in cDCs and pDCs. Arguing that such differences could not explain the discrepancies in antigen presentation by the two DC types, Young and colleagues have made an in-depth biochemical analysis of the trafficking and stability of MHC class II molecules in pDCs and cDCs and have identified many notable differences between pDCs and cDCs 1 .
